Investing.com - Aeglea Bio Therapeutics (NASDAQ: AGLE) reported second quarter EPS of $-2.250, $2.11 worse than the analyst estimate of $-0.143. Revenue for the quarter came in at $688K versus the consensus estimate of $198K.
Aeglea Bio Therapeutics's stock price closed at $0.520. It is up 261.110% in the last 3 months and down -0.200% in the last 12 months.
Aeglea Bio Therapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Aeglea Bio Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Aeglea Bio Therapeutics's Financial Health score is "fair performance".
Check out Aeglea Bio Therapeutics's recent earnings performance, and Aeglea Bio Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar